Share Name Share Symbol Market Type Share ISIN Share Description
Genflow Biosciences Plc LSE:GENF London Ordinary Share GB00BP2C3V08 ORD GBP0.0003
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -8.33% 1.65 1.60 1.70 1.80 1.65 1.80 475,707 11:25:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 5

Genflow Biosciences Share Discussion Threads

Showing 76 to 100 of 125 messages
Chat Pages: 5  4  3  2  1
Cheers felch, cheaps as chips, considering Genflow's potential and prospects in an area that is attracting so much investment, a bargain share price and lowly market cap which could explode Northwards at anytime, in the meantime upward momentum as the re-rate continues...a very exciting stock to hold imho Gl :-)
Another great find, moneymunch. It's great to still be able to invest in this stock at such an incredibly low price.
Scientists make big breakthroughs in unravelling the secret to reversing ageing

Experts say that it is easily possible to extend human life expectancy to way beyond current levels, a concept helped by billionaires pumping huge volumes of cash into the industry.

Kristen Fortney, CEO of San Francisco-based BioAge Labs, told Sky News: "There's no hard limits imposed by biology or by physics that says that we can't live better longer." And this is an area of scientific research that some of the world's richest entrepreneurs are taking an interest in.

Amazon founder Jeff Bezos, for instance, provided anti-ageing start-up Altos Labs with a huge $3billion (£2.5billion) cash injection.  And, this is not Mr Bezos' first venture into the anti-ageing domain either. 

The billionaire has also pumped cash into California-based firm UNITY Biotechnology, a start-up searching for therapies to slow or reverse the symptoms of ageing, with PayPal co-founder Peter Thiel also investing in the firm. According to a report by P&S Intelligence, the global anti-ageing market is predicted to skyrocket from around $191.5billion (£160billion) at current levels to a staggering $421.4billion (£352billion) by 2030. 

Due to the huge funding the industry is receiving, it is perhaps no wonder that exciting breakthroughs in the field are being found more regularly. 

Perfectly poised!!! Gla ;-)
A dead cert for longevity: why Sirt6 is the enzyme making headlines

The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.


But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only a few months ago, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that the mega-tech startup would team up with or outright buy Genflow Biosciences, launching its extremely undervalued share price to match, or exceed, its peer group.

Consider that on mere rumors of acquisition for their LIDAR IP, Microvision’s (MVIS) share price exploded almost 300% in less than 2 weeks last year.

Now imagine the sudden news that a Bezo’s backed company set on discovering the formula for immortality is acquiring or partnering with a little-known European biotech start-up with a share price of only 2p


News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.

Thanks for posting that moneymunch!
Longevity research is on the rise with Genflow latest to file for patent

Leila Hawkins | 06/10/2022

Genflow is the latest biotech company to announce that it is working on therapeutics targeting aging and age-related diseases.

The UK-based company is filing an international patent application in the US for variants of Sirtuin-6 (SIRT6), a gene variant found in centenarians that has been shown to promote longevity in mice.

SIRT6 has been labelled the “longevity sirtuin” as it has the capacity to repair DNA damage that contributes to aging. Researchers are studying its preventative potential for cardiovascular diseases in particular, as a lack of SIRT6 causes inflammation and cell damage that can lead to atherosclerosis and heart failure among other conditions.

The patent has been filed jointly with the University of Rochester, a prestigious private research university in New York. Genflow holds the exclusive license through the company’s Belgian subsidiary, Genflow Biosciences SRL. 

The rise of geroscience

Scientific research into longevity has ramped up in recent years, with the rise in demand for products and technologies that enable people to take control of their health and live for longer. 

Earlier this year biotech startup Altos Labs was formed, with a mission to develop cell therapies that can halt or reverse the aging process. The US$3  bn company is backed by Amazon founder Jeff Bezos and has been called “the best funded biotech start-up to date.”

In a further sign that longevity research - also known as geroscience - is set to become the next breakthrough area of scientific research, the kingdom of Saudi Arabia has formed Hevolution Foundation, a non-profit organization set to invest $1 bn a year in the study of aging and therapies that can extend people’s lives.

Commenting on the patent filing, Dr Eric Leire, Founder and CEO of Genflow, said: “I am proud of the excellent progress that Genflow has made by filing the patent and we look forward to contributing to the growing body of research on longevity, while also enhancing our patent portfolio. This marks a significant step in strengthening our IP position.”

Genflow Biosciences PLC (LSE:GENF) said it is confident about its future following three recent strategic collaborations in longevity research allied to a strong cash position.

In March, Genflow commenced a scientific research collaboration with the University of Rochester's Aging Research Center (RoAR), one of the world's pre-eminent age research facilities.

Data obtained from the collaboration will support the pre-clinical trials Genflow is undertaking and will expedite its development of gene therapies.

In May, the company entered into a collaborative research agreement with Organips, a France-based biotechnology company, while in June it partnered with Magnitude Biosciences, a UK-based, specialist biotechnology research organisation that supports drug discovery and product development.

Working with Magnitude will significantly expedite Genflow's future therapeutic developments, the company said.

Looking very nice. Gl :-)
Great spot, moneymunch. Huge upside from here. Looks like the rerate is getting under way.
Here's why this UK BioTech stock could be set to rally over 2000%

Here's why this UK BioTech stock could be set to rally over 2000%

Nice to see a bit of life in this.

Not sure why that is.

Very relaxed, company funded for next three years.

Be careful
What a disaster of a investment this has been to date
deadly nightshade
2 mm's have gone to the bid so 3 v 1 atm, probably trying to give it a nudge and generate some buying
2.75-2.755p spread

So now you can buy size at the bid price and a full penny lower than recent director buys.

I like the look of this company. Have been invested here for a couple of weeks now, price has dropped slightly since then but clearly plenty of upside potential. Credible team and well-funded. Can't see it hanging around at these levels for too long.
Evil overhang in this

NT to sell and 2.92p to buy, ignore the 3.5p offer mm are showing you can buy miles below that

directors paid 3.7p recently but nobody cares

3.34p paid for 127k

But I can buy at 3.15p so somebody overpaid there or should have split trade

Think there has been a overhang all along. Even when it was flying it was hard to get a sell quote and easy to buy.

Director buys in this market seem to mean nothing especially if small ones,

3-3.5p but you can buy miles inside at 3.17p

In this market MM's are frightened to hold any stock!
Below 3p -

Don't think there are too many sellers below that -

Chat Pages: 5  4  3  2  1
Your Recent History
Genflow Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230322 23:40:08